Advent will establish a portfolio of vascular access solutions with the potential to address the key gaps in enabling haemodialysis to be delivered in alternative care environments

Singapore-based medtech startup Advent Access, which focuses on end-stage renal disease management,  announced today certain key assets of Vital Access, a vascular technology company headquartered in the US.

The assets include the global manufacturing and commercialisation rights to the Vwing Vascular Needle Guide product line.

The acquisition is in line with Advent’s strategy to establish a portfolio of vascular access solutions with the potential to address the key gaps in enabling haemodialysis to be delivered in novel or alternative care environments, as per an official statement. It also enhances Advent’s potential global customer base and intellectual property portfolio.

Vwing is an implantable device designed to facilitate safe access to arteriovenous fistulas (AVF) in obese patients suffering from end-stage renal disease undergoing hemodialysis. Through AVF, patients gain access to their blood for cleaning via a dialysis machine.

Also Read: Viking Garage puts the brakes on dodgy bikes and rents out trusty roadsters like Harleys

Vwing is currently marketed in the US and also approved for use in markets including Europe, Canada and New Zealand.

The Vwing technology provides access to very deep fistulas and complements Advent’s av-Guardian technology, which is designed to be implantable for the majority of other fistula types.

Peh Ruey Feng, Founder and CEO of Advent Access, said: “This acquisition is a strategic move to broaden our vascular access portfolio and accelerate our access to key global markets, particularly the US. Advent now owns one of the industry’s most extensive IP portfolios in technology-assisted use of AV fistulas. Together with our core technology, the av-Guardian, we have the opportunity to create a leading portfolio of vascular access solutions, with the potential to enable hemodialysis to be provided beyond traditional care settings.”

Advent Access’s mission is to reduce dialysis cost and increase the quality of life of kidney failure patients. Its first product is av-Guardian — an implant technology that aims to improve vascular access reliability, and enable less-painful self-cannulation. av-Guardian forms a key component of Advent’s dialysis-machine agnostic platform to transform hemodialysis to be performed independently and safely.

In December last year, Advent Access raised US$1.9 million in pre-Series A funding round led by Temasek-backed medical device company Accuron MedTech.

The post Singapore’s medtech startup Advent Access acquires vascular tech company in US appeared first on e27.